Short Interest in Hypera S.A. (OTCMKTS:HYPMY) Drops By 99.1%

Hypera S.A. (OTCMKTS:HYPMY) was the target of a large drop in short interest in March. As of March 15th, there was short interest totalling 100 shares, a drop of 99.1% from the February 28th total of 11,300 shares. Based on an average trading volume of 15,800 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Hypera Trading Up 4.8 %

Shares of Hypera stock traded up $0.16 on Thursday, reaching $3.51. 424 shares of the company were exchanged, compared to its average volume of 8,591. The stock has a fifty day moving average price of $3.30 and a 200-day moving average price of $3.70. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 8.78 and a beta of 0.99. Hypera has a fifty-two week low of $2.64 and a fifty-two week high of $6.83.

Hypera (OTCMKTS:HYPMY) last issued its quarterly earnings data on Thursday, March 20th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $258.56 million during the quarter. Hypera had a net margin of 20.04% and a return on equity of 13.18%.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.